Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.
| Drug | Target | Relationship | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | Reposition | #cancers |
|---|---|---|---|---|---|---|---|---|---|---|---|
| fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study | HDAC3 | Direct | 2 | ||||||||
| pembrolizumab, guadecitabine, mocetinostat | HDAC3 | Direct | 2 | ||||||||
| 3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat | HDAC3 | Direct | 1 | ||||||||
| 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat | HDAC3 | Direct | 1 | ||||||||
| azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab | HDAC3 | Direct | 1 | ||||||||
| bevacizumab, temozolomide, vorinostat | HDAC3 | Direct | 1 | ||||||||
| capecitabine, vorinostat, radiotherapy, surgery to remove tumor | HDAC3 | Direct | 1 | ||||||||
| gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff | HDAC3 | Direct | 1 | ||||||||
| laboratory biomarker analysis, pharmacological study, temozolomide, vorinostat | HDAC3 | Direct | 1 | ||||||||
| pembrolizumab, vorinostat, temozolomide, radiotherapy | HDAC3 | Direct | 1 | ||||||||
| vorinostat, bevacizumab | HDAC3 | Direct | 1 | ||||||||
| vorinostat, bevacizumab, irinotecan | HDAC3 | Direct | 1 | ||||||||
| vorinostat, bortezomib, pharmacological study, laboratory biomarker analysis | HDAC3 | Direct | 1 | ||||||||
| vorinostat, conventional surgery | HDAC3 | Direct | 1 | ||||||||
| vorinostat, temozolomide, diagnostic laboratory biomarker analysis, pharmacological study | HDAC3 | Direct | 1 | ||||||||
| vorinostat, temozolomide, magnetic resonance spectroscopic imaging, survey administration | HDAC3 | Direct | 1 | ||||||||
| vorinostat, therapeutic conventional surgery, bortezomib | HDAC3 | Direct | 1 | ||||||||
| belinostat | HDAC3 | Direct | yes | 0 | |||||||
| panobinostat | HDAC3 | Direct | yes | 0 | |||||||
| panobinostat lactate | HDAC3 | Direct | yes | 0 | |||||||
| romidepsin | HDAC3 | Direct | yes | 0 | |||||||
| vorinostat | HDAC3 | Direct | yes | 0 | |||||||
| afatinib | EGFR | SSL via EGFR | yes | 2 | |||||||
| dacomitinib | EGFR | SSL via EGFR | yes | 2 | |||||||
| erlotinib | EGFR | SSL via EGFR | yes | 2 | |||||||
| gefitinib | EGFR | SSL via EGFR | yes | 2 | |||||||
| lazertinib and amivantamab | EGFR | SSL via EGFR | 1 | ||||||||
| osimertinib | EGFR | SSL via EGFR | yes | 1 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | AKT1 | SSL via AKT1 | 3 | ||||||||
| alendronate, etidronate, ibandronate, risedronate, raloxifene | ESR1 | SSL via ESR1 | 2 | ||||||||
| eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab | ESR1 | SSL via ESR1 | 2 | ||||||||
| entinostat | HDAC1 | SSL via HDAC1 | 2 | ||||||||
| fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study | HDAC1 | SSL via HDAC1 | 2 | ||||||||
| fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study | HDAC2 | SSL via HDAC2 | 2 | ||||||||
| gefitinib, fulvestrant, erlotinib | ESR1 | SSL via ESR1 | 2 | ||||||||
| pazopanib | SH2B3 | SSL via SH2B3 | 2 | ||||||||
| pembrolizumab, guadecitabine, mocetinostat | HDAC1 | SSL via HDAC1 | 2 | ||||||||
| pembrolizumab, guadecitabine, mocetinostat | HDAC2 | SSL via HDAC2 | 2 | ||||||||
| pharmacological study, romidepsin | HDAC1 | SSL via HDAC1 | 2 | ||||||||
| pharmacological study, romidepsin | HDAC2 | SSL via HDAC2 | 2 | ||||||||
| pharmacological study, romidepsin | HDAC4 | SSL via HDAC4 | 2 | ||||||||
| sy-5609, fulvestrant, gemcitabine, nab-paclitaxel | ESR1 | SSL via ESR1 | 2 | ||||||||
| 3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat | HDAC1 | SSL via HDAC1 | 1 | ||||||||
| 3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat | HDAC2 | SSL via HDAC2 | 1 | ||||||||
| 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat | HDAC1 | SSL via HDAC1 | 1 | ||||||||
| 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat | HDAC2 | SSL via HDAC2 | 1 | ||||||||
| adjuvant therapy, temozolomide, valproic acid, radiation therapy | HDAC1 | SSL via HDAC1 | 1 | ||||||||
| adjuvant therapy, temozolomide, valproic acid, radiation therapy | HDAC2 | SSL via HDAC2 | 1 | ||||||||
| adriamycin, cyclophosphamide, vindesine, valproic acid | HDAC1 | SSL via HDAC1 | 1 | ||||||||
| adriamycin, cyclophosphamide, vindesine, valproic acid | HDAC2 | SSL via HDAC2 | 1 | ||||||||
| arsenic trioxide | AKT1 | SSL via AKT1 | 1 | ||||||||
| arsenic trioxide | HDAC1 | SSL via HDAC1 | 1 | ||||||||
| arsenic trioxide, radiation therapy | AKT1 | SSL via AKT1 | 1 | ||||||||
| arsenic trioxide, radiation therapy | HDAC1 | SSL via HDAC1 | 1 | ||||||||
| arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy | AKT1 | SSL via AKT1 | 1 | ||||||||
| arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy | HDAC1 | SSL via HDAC1 | 1 | ||||||||
| atorvastatin, temozolomide, radiotherapy | HDAC2 | SSL via HDAC2 | 1 | ||||||||
| azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab | HDAC1 | SSL via HDAC1 | 1 | ||||||||
| azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab | HDAC2 | SSL via HDAC2 | 1 | ||||||||
| belinostat, cisplatin, etoposide | HDAC1 | SSL via HDAC1 | 1 | ||||||||
| bevacizumab, temozolomide, vorinostat | HDAC1 | SSL via HDAC1 | 1 | ||||||||
| bevacizumab, temozolomide, vorinostat | HDAC2 | SSL via HDAC2 | 1 | ||||||||
| biopsy, biospecimen collection, ceralasertib, computed tomography, echocardiography, multigated acquisition scan, positron emission tomography, trastuzumab deruxtecan | ATR | SSL via ATR | 1 | ||||||||
| blu-222, carboplatin, ribociclib, fulvestrant | ESR1 | SSL via ESR1 | 1 | ||||||||
| capecitabine, vorinostat, radiotherapy, surgery to remove tumor | HDAC1 | SSL via HDAC1 | 1 | ||||||||
| capecitabine, vorinostat, radiotherapy, surgery to remove tumor | HDAC2 | SSL via HDAC2 | 1 | ||||||||
| capivasertib | AKT1 | SSL via AKT1 | 1 | ||||||||
| ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin | TP53 | SSL via TP53 | 1 | ||||||||
| ceralasertib, olaparib, durvalumab | ATR | SSL via ATR | 1 | ||||||||
| cisplatin, carboplatin, etoposide, durvalumab, ceralasertib | ATR | SSL via ATR | 1 | ||||||||
| cytoreductive surgery, perifosine, temsirolimus | AKT1 | SSL via AKT1 | 1 | ||||||||
| decitabine, gemcitabine | HDAC1 | SSL via HDAC1 | 1 | ||||||||
| entinostat, nivolumab, entinostat, nivolumab | HDAC1 | SSL via HDAC1 | 1 | ||||||||
| enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) | AKT1 | SSL via AKT1 | 1 | ||||||||
| enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) | PIK3R1 | SSL via PIK3R1 | 1 | ||||||||
| enzastaurin, lomustine | AKT1 | SSL via AKT1 | 1 | ||||||||
| enzastaurin, lomustine | PIK3R1 | SSL via PIK3R1 | 1 | ||||||||
| enzastaurin, temozolomide, radiation therapy | AKT1 | SSL via AKT1 | 1 | ||||||||
| enzastaurin, temozolomide, radiation therapy | PIK3R1 | SSL via PIK3R1 | 1 | ||||||||
| fingolimod | HDAC1 | SSL via HDAC1 | 1 | ||||||||
| gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff | HDAC1 | SSL via HDAC1 | 1 | ||||||||
| gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff | HDAC2 | SSL via HDAC2 | 1 | ||||||||
| genistein, erlotinib hydrochloride, gemcitabine hydrochloride | AKT1 | SSL via AKT1 | 1 | ||||||||
| genistein, erlotinib hydrochloride, gemcitabine hydrochloride | ESR1 | SSL via ESR1 | 1 | ||||||||
| irinotecan, cisplatin, simvastatin | HDAC2 | SSL via HDAC2 | 1 | ||||||||
| laboratory biomarker analysis, perifosine, temsirolimus, therapeutic conventional surgery | AKT1 | SSL via AKT1 | 1 | ||||||||
| laboratory biomarker analysis, pharmacological study, temozolomide, vorinostat | HDAC1 | SSL via HDAC1 | 1 | ||||||||
| laboratory biomarker analysis, pharmacological study, temozolomide, vorinostat | HDAC2 | SSL via HDAC2 | 1 | ||||||||
| levonorgestrel, metformin | ESR1 | SSL via ESR1 | 1 | ||||||||
| omeprazole, melatonin | ESR1 | SSL via ESR1 | 1 | ||||||||
| pazopanib, 5-fu, oxaliplatin, leukovorin (flo) | SH2B3 | SSL via SH2B3 | 1 | ||||||||
| pazopanib, lapatinib | SH2B3 | SSL via SH2B3 | 1 | ||||||||
| pazopanib, placebo | SH2B3 | SSL via SH2B3 | 1 | ||||||||
| pegilodecakin, paclitaxel or docetaxel and carboplatin or cisplatin, folfox (oxaliplatin/leucovorin/5-fluorouracil), gemcitabine/nab-paclitaxel, capecitabine, pazopanib, pembrolizumab, paclitaxel, nivolumab, gemcitabine/carboplatin | SH2B3 | SSL via SH2B3 | 1 | ||||||||
| pembrolizumab, vorinostat, temozolomide, radiotherapy | HDAC1 | SSL via HDAC1 | 1 | ||||||||
| pembrolizumab, vorinostat, temozolomide, radiotherapy | HDAC2 | SSL via HDAC2 | 1 | ||||||||
| perifosine | AKT1 | SSL via AKT1 | 1 | ||||||||
| pf-07220060, letrozole, fulvestrant, midazolam, enzalutamide | ESR1 | SSL via ESR1 | 1 | ||||||||
| porfimer sodium | LDLR | SSL via LDLR | 1 | ||||||||
| porfimer sodium, adjuvant therapy, conventional surgery | LDLR | SSL via LDLR | 1 |